DDInter1137 DDInter624
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) interacts with {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) regulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Indinavir
Indinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Medroxyprogesterone acetate (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Medroxyprogesterone acetate (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Medroxyprogesterone acetate (Compound) downregulates MYC (Gene) and MYC (Gene) interacts with RFC2 (Gene) and RFC2 (Gene) is downregulated by Efavirenz (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Medroxyprogesterone acetate (Compound) downregulates MYC (Gene) and MYC (Gene) regulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Indinavir and Indinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)